COMUNICADO: Wyeth and Progenics Receive Positive Opinion From European Committee for RELISTOR for the Treatment of Opioid-Induced C

Actualizado 25/04/2008 0:14:57 CET

PROGENICS DISCLOSURE NOTICE: The information contained in this document is current as of April 24, 2008. This press release contains forward-looking statements. Any statements contained herein that are not statements of historical fact may be forward-looking statements. When the Company uses the words "anticipates," "plans," "expects" and similar expressions, it is identifying forward-looking statements. Such forward-looking statements involve risks and uncertainties which may cause the Company's actual results, performance or achievements to be materially different from those expressed or implied by forward-looking statements. Such factors include, among others, the uncertainties associated with product development, the risk that clinical trials will not commence or proceed as planned, the risks and uncertainties associated with dependence upon the actions of our corporate, academic and other collaborators and of government regulatory agencies, the risk that our licenses to intellectual property may be terminated because of our failure to have satisfied performance milestones, the risk that products that appear promising in early clinical trials do not demonstrate efficacy in larger-scale clinical trials, the risk that we may not be able to manufacture commercial quantities of our products, the uncertainty of future profitability and other factors set forth more fully in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2007, and other reports filed with the Securities and Exchange Commission, to which investors are referred for further information. In particular, the Company cannot assure you that any of its programs will result in a commercial product. Progenics does not have a policy of updating or revising forward-looking statements and assumes no obligation to update any forward-looking statements contained in this document as a result of new information or future events or developments. Thus, it should not be assumed that the Company's silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements.

Editor's Note:

Additional information on Wyeth is available at

Additional information on Progenics is available at

Web site:

Wyeth: Media, Sal Foti, Wyeth Pharmaceuticals, +1-484-865-3490, Douglas Petkus, Wyeth, +1-484-865-5140, Gwen Fisher, Wyeth Pharmaceuticals, +1-484-865-5160, or Investors, Justin Victoria, Wyeth, +1-973-660-5340; or Progenics Pharmaceuticals, Inc.: Investors, Richard W. Krawiec, Ph.D., Vice President, Corporate Affairs, +1-914-789-2814,, Dory A. Lombardo, Senior Manager, Corporate Affairs, +1-914-789-2818,, Media, Aline Schimmel, WeissComm Partners, +1-312-284-4706, Julie Normart, WeissComm Partners, +1-415-946-1087

Mejora la comunicación de tu empresa con Europa Press Comunicación

Mejora la comunicación de tu empresa con Europa Press Comunicación